The effect of acute administration of statins on coronary microcirculation during the pre-revascularization period in patients with myocardial infraction

Atherosclerosis

Volumn 223, Issue 1, 2012, Pages 184-189

  Paraskevaidis, Ioannis A ^a   Iliodromitis, Efstathios K ^a   Ikonomidis, Ignatios ^a   Rallidis, Loukianos ^a   Hamodraka, Eftihia ^a   Parissis, John ^a   Andoniadis, Aias ^a   Tzortzis, Stavros ^a   Anastasiou Nana, Maria ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Contrast echocardiography; Coronary microcirculation; Myocardial infraction; Post conditioning; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; FONDAPARINUX; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE;

ADULT; ARTICLE; BLOOD VOLUME; CLINICAL ARTICLE; CONTRAST ECHOCARDIOGRAPHY; CORONARY ARTERY BLOOD FLOW; DRUG EFFECT; DRUG USE; FEMALE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE WALL MOTION; HEART MUSCLE REPERFUSION; HUMAN; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

AGED; ANGIOPLASTY, BALLOON, CORONARY; BLOOD FLOW VELOCITY; CHI-SQUARE DISTRIBUTION; COMBINED MODALITY THERAPY; CONTRAST MEDIA; CORONARY CIRCULATION; ECHOCARDIOGRAPHY; FEMALE; GREECE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LINEAR MODELS; MALE; MICROCIRCULATION; MIDDLE AGED; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; PHOSPHOLIPIDS; PREDICTIVE VALUE OF TESTS; REGIONAL BLOOD FLOW; STENTS; STROKE VOLUME; SULFUR HEXAFLUORIDE; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 84863096401     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.04.002     Document Type: Article

References (38)

1. Herrmann J. Peri-procedural myocardial injury. Eur Heart J 2005, 26:2493-2519.
2. Ege E., Dereli Y., Kurban S., Sarigül A. Atorvastatin pretreatment diminishes the levels of myocardial ischemia markers early after CABG operation: an observational study. J Cardiothorac Surg 2010, 5:60.
3. Mannacio V.A., Iorio D., De Amicis V., Di Lello F., Musumeci F. Effect of rosuvastatin pretreatment on myocardial damage after coronary surgery: a randomized trial. J Thorac Cardiovasc Surg 2008, 136:1541-1548.
4. Pascual D.A., Arribas J.M., Tornel P.L., et al. Preoperative statin therapy and troponin T predict early complications of coronary artery surgery. Ann Thorac Surg 2006, 81:78-83.
5. Magovern J.A., Moraca R.J., Bailey S.H., et al. Preoperative statin is associated with decreased operative mortality in high risk coronary artery bypass patients. J Cardiothorac Surg 2010, 5:8.
6. Heeschen C., Hamm C.W., Laufs U., Snapinn S., Böhm M., White H.D. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002, 105:1446-1452.
7. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The long-term intervention with pravastatin in ischaemic disease (LIPID) study group. N Engl J Med 1998, 339:1349-1357.
8. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004, 109:39-43.
9. Morikawa S., Takabe W., Mataki C., et al. The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells. J Atheroscler Thromb 2002, 9:178-183.
10. Lepper W., Sieswerda G.T., Franke A., et al. Repeated assessment of coronary flow velocity pattern in patients with first acute myocardial infarction. J Am Coll Cardiol 2002, 39:1283-1289.
11. Yellon D.M., Hausenloy D.J. Myocardial reperfusion injury. N Engl J Med 2007, 357:1121-1135.
12. Piper H.M., Garcia-Dorado D., Ovize M. A fresh look at reperfusion injury. Cardiovasc Res 1998, 38:291-300.
13. Vinten-Johansen J., Zhao Z.Q., Jiang R., Zatta A.J., Dobson G.P. Preconditioning and postconditioning: innate cardioprotection from ischemia-reperfusion injury. J Appl Physiol 2007, 103:1441-1448.
14. Zhao Z.-Q., Corvera J.S., Halkos M.E., et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol 2003, 285:H579-H588.
15. Iliodromitis E.K., Paraskevaidis I.A., Fountoulaki K., et al. Staccato reperfusion prevents reperfusion injury in patients undergoing coronary angioplasty: a 1-year follow-up study. Atherosclerosis 2009, 204:497-502.
16. Ikonomidis I., Iliodromitis E.K., Tzortzis S., et al. Staccato reperfusion improves myocardial microcirculatory function and long-term left ventricular remodelling: a randomised contrast echocardiography study. Heart 2010, 96:1898-1903.
17. Shimoni S., Frangogiannis N.G., Aggeli C.J., et al. Microvascular structural correlates of myocardial contrast echocardiography in patients with coronary artery disease and left ventricular dysfunction: implications for the assessment of myocardial hibernation. Circulation 2002, 106:950-956.
18. Shimoni S., Frangogiannis N.G., Aggeli C.J., et al. Identification of hibernating myocardium with quantitative intravenous myocardial contrast echocardiography: comparison with dobutamine echocardiography and thallium-201 scintigraphy. Circulation 2003, 107:538-544.
19. Funaro S., La Torre G., Madonna M., et al. Incidence, determinants, and prognostic value of reverse left ventricular remodelling after primary percutaneous coronary intervention: results of the acute myocardial infarction contrast imaging (AMICI) multicenter study. Eur Heart J 2009, 30:566-575. on behalf of AMICI Investigators.
20. Galiuto L., Gabrielli F.A., Lombardo A., et al. Reversible microvascular dysfunction coupled with persistent myocardial dysfunction: implications for post-infarct left ventricular remodeling. Heart 2007, 93:565-571.
21. Abdelmoneim S.S., Dhoble A., Bernier M., et al. Absolute myocardial blood flow determination using real-time myocardial contrast echocardiography during adenosine stress: comparison with single photon emission computed tomography. Heart 2009, 95:1662-1668.
22. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
23. Cannon C.P., McCabe C.H., Belder R., Breen J., Braunwald E. Design of the pravastatin or atorvastatin evaluation and infection therapy (PROVE IT)-TIMI 22 trial. Am J Cardiol 2002, 89:860-861.
24. Kinlay S., Schwartz G.G., Olsson A.G., et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003, 108:1560-1566.
25. Muhlestein J.B., Horne B.D., Bair T.L., et al. Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. Am J Cardiol 2001, 87:257-261.
26. Jones S.P., Lefer D.J. Cardioprotective action of acute HMG-CoA reductase inhibition in the setting of myocardial infarction. Acta Physiol Scand 2001, 173:139-143.
27. Notarbartolo A., Davi G., Averna M., et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995, 15:247-251.
28. Plenge J.K., Hernandez T.L., Weil K.M., et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002, 106:1447-1452.
29. Iliodromitis E.K., Andreadou I., Prokovas E., et al. Simvastatin in contrast to postconditioning reduces infarct size in hyperlipidemic rabbits: possible role of oxidative/nitrosative stress attenuation. Basic Res Cardiol 2010, 105:193-203.
30. Sanada S., Asanuma H., Minamino T., et al. Optimal windows of statin use for immediate infarct limitation. 5'-Nucleotidase as another downstream molecule of phosphatidylinositol 3-kinase. Circulation 2004, 110:2143-2149.
31. Vilahur G., Casani L., Pena E., Duran X., Juan-Babot O., Badimon L. Induction of RISK by HMG-CoA reductase inhibition affords cardioprotection after myocardial infarction. Atherosclerosis 2009, 206:95-101.
32. Takemoto M., Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001, 21:1712-1719.
33. Dereli Y., Ege E., Kurban S., Narin C., Sarigül A., Yeniterzi M. Pre-operative atorvastatin therapy to decrease the systemic inflammatory response after coronary artery bypass grafting. J Int Med Res 2008, 36:1248-1254.
34. Andreadou I., Farmakis D., Prokjovas E., et al. Short-term statin administration in hypercholesterolemic rabbits resistant to postconditioning: effects on infarct size, endothelial nitric oxide synthase and nitro-oxidative stress. Cardiovasc Res 2012, March 12 (Epub ahead of print).
35. Sanguigni V., Pignatelli P., Lenti L., et al. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation 2005, 111:412-419.
36. Hausenloy D.J., Yellon D.M. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev 2007, 12:217-234.
37. Patti G., Chello M., Pasceri V., et al. Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of Myocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy. J Am Coll Cardiol 2006, 48:1560-1566.
38. Gatto L., Patti G., Chello M., et al. Procedural myocardial protection by short-term atorvastatin load is related to lower levels of adhesion molecules after PCI in patients with ACS. Results from the ARMYDA-ACS CAMs substudy. G Ital Cardiol 2009, 10:159S.